These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7085041)

  • 1. Inhibition by nonsteroidal antiinflammatory drugs of luminol-dependent human-granulocyte chemiluminescence and [3H]FMLP binding. Effect of sulindac sulfide, indomethacin metabolite, and optical enantiomers (+) and (-) MK830.
    Van Dyke K; Peden D; Van Dyke C; Jones G; Castranova V; Ma J
    Inflammation; 1982 Mar; 6(1):113-25. PubMed ID: 7085041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indomethacin is a competitive inhibitor of the binding of the chemotactic peptide formyl-Met-Leu-Phe to human polymorphonuclear leukocytes.
    Abita JP
    Agents Actions; 1981 Dec; 11(6-7):610-2. PubMed ID: 6803537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5,8,11,14-Eicosatetraynoic acid (ETYA) inhibits binding of N-formyl-methionyl-leucyl-phenylalanine (FLMP) to its receptor on human granulocytes. A note of caution.
    Atkinson JP; Simchowitz L; Mehta J; Stenson WF
    Immunopharmacology; 1982 Feb; 4(1):1-9. PubMed ID: 6277829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new screening system for nonsteroidal anti-inflammatory drugs based upon inhibition of chemiluminescence produced from human cells (granulocytes).
    Van Dyke K; Van Dyke C; Udeinya J; Brister C; Wilson M
    Clin Chem; 1979 Sep; 25(9):1655-61. PubMed ID: 466792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fate of the N-formyl-chemotactic peptide receptor in stimulated human granulocytes: subcellular fractionation studies.
    Jesaitis AJ; Naemura JR; Painter RG; Schmitt M; Sklar LA; Cochrane CG
    J Cell Biochem; 1982; 20(2):177-91. PubMed ID: 6302115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luminol-amplified chemiluminescence activity in human monocytes: a comparison with the activity induced in granulocytes.
    Johansson A; Dahlgren C
    J Biolumin Chemilumin; 1990; 5(1):37-41. PubMed ID: 2156407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes.
    Matamoros MC; Walker BK; Van Dyke K; Van Dyke CJ
    Pharmacology; 1983; 27(1):29-39. PubMed ID: 6611646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of indomethacin on the binding of the chemotactic peptide formyl-Met-Leu-Phe on human polymorphonuclear leukocytes.
    Cost H; Gespach C; Abita JP
    FEBS Lett; 1981 Sep; 132(1):85-8. PubMed ID: 6271584
    [No Abstract]   [Full Text] [Related]  

  • 9. The onset of polymorphonuclear leucocyte membrane-stimulated metabolic activity.
    Williams AJ; Cole PJ
    Immunology; 1981 Aug; 43(4):733-9. PubMed ID: 7275176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fate of an N-formylated chemotactic peptide in stimulated human granulocytes. Subcellular fractionation studies.
    Jesaitis AJ; Naemura JR; Painter RG; Sklar LA; Cochrane CG
    J Biol Chem; 1983 Feb; 258(3):1968-77. PubMed ID: 6822545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of polymorphonuclear leukocyte chemiluminescent response to the chemoattractant f-Met-Leu-Phe.
    Dahlgren C; Magnusson KE; Stendahl O; Sundqvist T
    Int Arch Allergy Appl Immunol; 1982; 68(1):79-83. PubMed ID: 6281196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of granulocyte response to the chemoattractant F-Met-Leu-Phe.
    Dahlgren C; Stendahl O
    Adv Exp Med Biol; 1982; 155():107-12. PubMed ID: 6297266
    [No Abstract]   [Full Text] [Related]  

  • 13. Antioxidation theory of non-steroidal anti-inflammatory drugs based upon the inhibition of luminol-enhanced chemiluminescence from the myeloperoxidase reaction.
    Pekoe G; Van Dyke K; Peden D; Mengoli H; English D
    Agents Actions; 1982 Jul; 12(3):371-6. PubMed ID: 6291348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sulindac and indomethacin on renal prostaglandin synthesis.
    Sedor JR; Williams SL; Chremos AN; Johnson CL; Dunn MJ
    Clin Pharmacol Ther; 1984 Jul; 36(1):85-91. PubMed ID: 6428794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of myeloperoxidase in luminol-dependent chemiluminescence of polymorphonuclear leukocytes.
    Dahlgren C; Stendahl O
    Infect Immun; 1983 Feb; 39(2):736-41. PubMed ID: 6299947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of the luminol-dependent chemiluminescence of granulocytes].
    Smoligovets EO; Fedorov NA; Malykhina LS
    Lab Delo; 1989; (2):23-6. PubMed ID: 2467051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative metabolism of circulating granulocytes in adult respiratory distress syndrome.
    Tagan MC; Markert M; Schaller MD; Feihl F; Chiolero R; Perret CH
    Am J Med; 1991 Sep; 91(3C):72S-78S. PubMed ID: 1928215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac is not renal sparing in man.
    Roberts DG; Gerber JG; Barnes JS; Zerbe GO; Nies AS
    Clin Pharmacol Ther; 1985 Sep; 38(3):258-65. PubMed ID: 4028619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of oxamethacin and sulindac on prostaglandin synthesis].
    Damas J; Volon G
    C R Seances Soc Biol Fil; 1979; 173(4):849-53. PubMed ID: 160831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotactic receptor of cord blood granulocytes to the synthesized chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine.
    Nunoi H; Endo F; Chikazawa S; Namikawa T; Matsuda I
    Pediatr Res; 1983 Jan; 17(1):57-60. PubMed ID: 6300743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.